The Trump administration’s cuts to a global AIDS relief program threaten to upend rollout of a groundbreaking HIV prevention ...

US pharmaceutical company Eli Lilly has launched Mounjaro, a diabetes and weight-loss drug, in India. Priced at Rs 3,500 for a 2.5 mg vial, the ‘game-changing’ medication has debuted in the Indian ...

We recently published a list of Billionaire Ken Fisher’s Top 13 Growth Stock Picks. In this article, we are going to take a ...

Healthcare & Pharmaceuticalscategory· March 21, 2025 Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market Eli Lilly launched its blockbuster diabetes and ...

Pressure may grow on companies to repatriate production, raising production costs and potentially medicine prices too.

Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.

Mounjaro and Zepbound are Eli Lilly's largest sources of growth, but there is much more to the company. Over the last couple of years, the pharmaceutical sector has captivated investors thanks in ...

Shares of the company were up 8.5% in afternoon trading. The telehealth firm is following its peers Teladoc and LifeMD in offering Lilly's Zepbound ahead of restrictions on selling copies known as ...

Now, Eli Lilly, the largest pharmaceutical company in the world in terms of market capitalisation, has launched its own version of the magic drug. Tirzepatide, or Mounjaro, as the company is ...

Eli Lilly and Company launched its weight loss drug Mounjaro in India on Thursday after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO). This is a drug which ...

Eli Lilly launches Mounjaro in India, targeting the $150B weight-loss market. The GLP-1 drug offers diabetes control & major ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India, marking its entry into a rapidly growing market.